About Azitra Inc (AZTR)
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
AZTR Key Statistics
| Current Price | $0.18 | Market Cap | $2 million |
|---|---|---|---|
| Daily Change | -7.08% | Volume | 1.4M |
| 52-Week High | $2.66 | 52-Week Low | $0.15 |
| Sector | Healthcare | Industry | Biotechnology |
AZTR Price Performance
Azitra Inc stock has returned -5.26% over the past day, +0.00% over the past week, -14.29% over the past month, and -35.71% over the past three months. The stock trades between a 52-week low of $0.15 and a high of $2.66.